

RESEARCH

Open Access



Production, secretion and purification of a correctly folded staphylococcal antigen in *Lactococcus lactis*

Frédéric Samazan^{1,2}, Bachra Rokbi³, Delphine Seguin³, Fabienne Telles³, Valérie Gautier⁴, Gilbert Richarme⁴, Didier Chevret¹, Paloma Fernández Varela⁵, Christophe Velours⁵ and Isabelle Poquet^{1,6*}

Abstract

Background: *Lactococcus lactis*, a lactic acid bacterium traditionally used to ferment milk and manufacture cheeses, is also, in the biotechnology field, an interesting host to produce proteins of medical interest, as it is “Generally Recognized As Safe”. Furthermore, as *L. lactis* naturally secretes only one major endogenous protein (Usp45), the secretion of heterologous proteins in this species facilitates their purification from a protein-poor culture medium. Here, we developed and optimized protein production and secretion in *L. lactis* to obtain proteins of high quality, both correctly folded and pure to a high extent. As proteins to be produced, we chose the two transmembrane members of the HtrA protease family in *Staphylococcus aureus*, an important extra-cellular pathogen, as these putative surface-exposed antigens could constitute good targets for vaccine development.

Results: A recombinant ORF encoding a C-terminal, soluble, proteolytically inactive and tagged form of each staphylococcal HtrA protein was cloned into a lactococcal expression-secretion vector. After growth and induction of recombinant gene expression, *L. lactis* was able to produce and secrete each recombinant rHtrA protein as a stable form that accumulated in the culture medium in similar amounts as the naturally secreted endogenous protein, Usp45. *L. lactis* growth in fermenters, in particular in a rich optimized medium, led to higher yields for each rHtrA protein. Protein purification from the lactococcal culture medium was easily achieved in one step and allowed recovery of highly pure and stable proteins whose identity was confirmed by mass spectrometry. Although rHtrA proteins were monomeric, they displayed the same secondary structure content, thermal stability and chaperone activity as many other HtrA family members, indicating that they were correctly folded. rHtrA protein immunogenicity was established in mice. The raised polyclonal antibodies allowed studying the expression and subcellular localization of wild type proteins in *S. aureus*: although both proteins were expressed, only HtrA₁ was found to be, as predicted, exposed at the staphylococcal cell surface suggesting that it could be a better candidate for vaccine development.

Conclusions: In this study, an efficient process was developed to produce and secrete putative staphylococcal surface antigens in *L. lactis* and to purify them to homogeneity in one step from the culture supernatant. This allowed recovering fully folded, stable and pure proteins which constitute promising vaccine candidates to be tested for protection against staphylococcal infection. *L. lactis* thus proved to be an efficient and competitive cell factory to produce proteins of high quality for medical applications.

Keywords: *Lactococcus lactis*, Cell factory, Secretion, *Staphylococcus aureus* antigen, HtrA family, Soluble recombinant protein, Chaperone

*Correspondence: isabelle.poquet@jouy.inra.fr

⁶ Present Address: LPBA, Institut Pasteur, Bât. Calmette, 75015 Paris, France

Full list of author information is available at the end of the article

Background

Lactococcus lactis, a Gram-positive lactic acid bacterium and a classical starter for the manufacture of cheeses, can be used as a cell factory to produce proteins of interest [1–6]. As a long known innocuous, Generally Recognised As Safe (“GRAS”) food-grade species [7], *L. lactis* is an interesting host to produce proteins of medical interest [2, 4, 5]. Compared to *Escherichia coli*, the advantage of *L. lactis* is that it does not produce endotoxin (lipopolysaccharide) [2, 4, 5] which has to be removed from protein preparations before medical use [8]. In contrast to *Bacillus subtilis*, *L. lactis* secretes only one major endogenous protein, Usp45, and no proteases [9]: a strategy combining production and secretion of heterologous proteins in *L. lactis* is thus interesting as it facilitates protein purification from the culture medium [4]. As secreted heterologous proteins can be degraded by the lactococcal surface protease HtrA, protein yield can be improved by the use of a mutant strain devoid of this surface proteolytic activity [10].

Several tools have been developed for protein production in *L. lactis*, in particular expression systems and vectors [11–13], secretion signals [4, 14, 15] and expression-secretion vectors [4, 13, 16, 17]. Proteins of medical interest have been successfully produced and secreted by *L. lactis*, in general to be delivered to a host [1, 2], and in a few cases to be purified [16, 18]. In our laboratory, a tightly regulated expression system (ZitR-regulated P_{zit} promoter) [11, 19], an efficient export signal (SP_{Exp4} signal peptide) [4, 20], expression-secretion vectors [4, 21] and mutant host strains devoid of surface proteolytic activity [10, 22, 23] have been developed for *L. lactis* and used for protein production and secretion [4, 21, 22, 24]. Furthermore, an enzyme of biotechnological interest, the staphylococcal nuclease, which is naturally secreted, could be produced, secreted and purified in *L. lactis* [21]. Here, we developed, in *L. lactis*, the secretion of high quality proteins for medical applications. We chose, as model proteins, putative surface-exposed antigens and virulence factors: the two HtrA family members of *Staphylococcus aureus*, an important extra-cellular pathogen species.

The HtrA family is composed of highly conserved, extra-cytoplasmic serine proteases [25, 26]. In prokaryotes, they are located in the cell envelope: in either the periplasm or the cytoplasmic membrane in Gram-negative bacteria, and in the cytoplasmic membrane in Gram-positive bacteria. Although some HtrA proteases, like *E. coli* DegS, have a regulatory function, most of them are involved in the protein quality control in the bacterial cell envelope [25–27]. They are often essential for survival to various stress conditions, notably heat [28, 29] and/or oxidative stress [30], because they alleviate protein

unfolding and misfolding [25, 27]. They can act both as proteases to degrade proteins and as chaperones to assist them in folding, like *E. coli* DegP/HtrA, the family model [25, 27].

In many pathogens, HtrA proteins are involved in virulence [31]. Several models have been proposed to account for this role. First, HtrA proteases could, under the stress conditions prevailing in the host during infection, degrade unfolded and misfolded proteins and thus indirectly improve cellular fitness and survival [30]. Second, HtrA proteases could play a direct role by processing endogenous, folded, wild type (WT) proteins, as first demonstrated in *L. lactis*, a food-grade species [10, 32] (and unpublished data), and subsequently confirmed in a pathogenic species, *Bacillus anthracis*, even though in that case the HtrA target is not a virulence factor [33]. Third, in some Gram-negative pathogens, HtrA proteases could target host proteins like E-cadherin [34–36] or the interleukin IL8 [37], even if it remains unclear how intra-cellular HtrA proteins are able to reach their extra-cellular host targets [37, 38]. Finally, HtrA proteins could also contribute to virulence as chaperones, either by enhancing in vivo growth and survival, [39], or by improving the folding of a virulence factor [40], or even by contributing to bacteria–host interaction [41].

In pathogens, HtrA proteins are also often important antigens. In several species, they were found to be immunogenic in vivo, in either infected [42–44] or convalescent hosts (animals or human patients) [43–49], even though in *Chlamydia trachomatis* the meaning of these results with respect to disease remains controversial [50, 51]. Moreover, purified HtrA proteins from some Gram-negative pathogens were shown to be protective against infection [45, 49, 52–54] even though this was not always the case [55, 56]. Surprisingly, to our knowledge, no such protection studies have been performed using HtrA proteins of Gram-positive extra-cellular pathogens, despite the fact that, as cell surface exposed proteins, they could be recognized by circulating antibodies at an early infection step and might thus constitute good targets for vaccine development.

In *S. aureus*, an extra-cellular pathogenic species, we previously identified and studied two putative trans-membrane members of the HtrA family: HtrA₁ and HtrA₂ [23, 57]. WT HtrA₁ protein from strain RN6390 was found to display extra-cellular proteolytic activity when over-produced in *L. lactis* [23]. Furthermore, both HtrA proteins were, together, implicated in the virulence and extra-cellular proteome composition of strain RN6390, and each of them was involved in the stress resistance of strain COL [57]. In an independent study, among a peptide library from strain COL, a few HtrA₁ peptides were found to be antigenic and to elicit

an immunological response in vivo, in infected patients [48]. As predicted surface-exposed proteins, staphylococcal HtrA proteins from strain COL, and in particular the HtrA₁ antigen, constitute interesting vaccine candidates [58], and they were thus chosen to be produced in *L. lactis* and purified. Recombinant ORFs encoding soluble, proteolytically inactive and tagged HtrA forms were cloned into a lactococcal expression and secretion vector. Recombinant rHtrA protein yield was evaluated after lactococcal growth in rich medium in flasks or in fermenters after medium optimization. After lactococcal growth in the optimized rich medium in fermenters and induction of gene expression, secreted rHtrA proteins were purified in one step from the culture medium. After confirming their identity by mass spectrometry, rHtrA proteins were analysed in vitro for their secondary structures, stability, oligomeric state and chaperone activity, in order to analyze their folding. Finally, their immunogenicity was tested in mice, and the generated antibodies allowed studying the expression and cell surface exposure of WT HtrA proteins in *S. aureus*.

Methods

Bacterial strains and growth conditions

Bacterial strains and plasmids used in this study are described in Table 1. *E. coli* strain JM109 (Promega) and its derivatives carrying plasmids were grown at 37°C, with shaking, in LB medium supplemented with 100 µg/mL ampicillin when necessary for plasmid selection. *L. lactis* strain MG1363 (WT) and its recombinant derivatives carrying plasmids were grown at 30°C in rich M17 medium supplemented with glucose in batch and in a slightly different medium (supplemented by more concentrated glucose and more buffered) in fermenters (see below 'Recombinant protein production in *L. lactis*'). Chloramphenicol at 10 µg/mL was added when necessary for plasmid selection. *S. aureus* strain Lowenstein (ATCC 49521) and *htrA* mutants of strain COL [57] were grown at 37°C, with shaking, in two media: (1) SATA-2 medium (a Sanofi Pasteur proprietary medium [59]: wheat peptone 93 g/L, D-glucose 0.25 g/L; NaCl 41 g/L, MgCl₂ 15 g/L), and (2) TSB medium (Difco, Sparks, MD, USA), supplemented or not with 2,2'-Dipyridyl at 1 mM (Sigma-Aldrich).

Table 1 Bacterial strains and plasmids used in this study

(A) Bacterial strains		
Names	Genotype, characteristics	Reference
<i>Escherichia coli</i>		
JM109	<i>endA1, recA1, gyrA96, thi, hsdR17</i> (<i>r_K⁻, m_K⁺</i>), <i>relA1, supE44, Δ(lac-proAB)</i> , [<i>F'</i> <i>traD36, proAB, laqI^qZΔM15</i>]	Promega
<i>Lactococcus lactis</i>		
MG1363	plasmid free derivative of NCD0712	Laboratory collection
<i>S. aureus</i>		
Lowenstein (ATCC 49521)	clinical isolate, capsular polysaccharide CP5-positive	Laboratory collection
COL	clinical isolate, methicillin resistant	Laboratory collection
<i>htrA₁</i>	COL <i>htrA₁ :: cat</i> , Cm ^R	[57]
<i>htrA₂</i>	COL <i>htrA₂ :: spc</i> , Spc ^R	[57]
(B) Plasmids		
Names	Characteristics	Reference
pGEM ^T	T-tailed PCR product Cloning vector, Amp ^R	Promega
pVE8124	pGEM ^T derivative where recombinant <i>htrA_{1r}</i> ORF is cloned <i>htrA_{1r}</i> encodes HtrA ₁ -ΔTM-Ser ₂₅₅ Ala-His ₆ protein	This work
pVE8125	pGEM ^T derivative where recombinant <i>htrA_{2r}</i> ORF is cloned <i>htrA_{2r}</i> encodes SP _{Exp4} -HtrA ₂ -ΔTM-Ser ₆₁₉ Ala-His ₆ protein	This work
pLB145	pWV01; Cm ^R ; expression-secretion vector where <i>exp4_{sp}-nuc</i> is cloned under the control of a lactococcal expression system, P _{zit} <i>zitR</i> <i>exp4_{sp}-nuc</i> encodes a hybrid protein between a lactococcal signal peptide (SP _{Exp4}) and the mature secreted form of the staphylococcal nuclease (NucB)	[4]
pVE8126	pLB145 derivative where <i>htrA_{1r}</i> ORF is cloned in place of <i>nuc</i> ORF to be fused in frame to <i>exp4_{sp}</i> <i>exp4_{sp}-htrA_{1r}</i> encodes a hybrid precursor leading to secreted rHtrA ₁ protein	This work
pVE8127	pLB145 derivative where <i>htrA_{2r}</i> ORF is cloned in place of <i>exp4_{sp}-nuc</i> ORF <i>htrA_{2r}</i> encodes a hybrid precursor leading to secreted rHtrA ₂ protein	This work

Amp^R ampicillin resistant, Cm^R chloramphenicol resistant, Spc^R spectinomycin resistant.

PCR and cloning

High-fidelity PCRs using chromosomal DNA from *S. aureus* strain COL as a template were performed to obtain recombinant ORFs encoding N-terminally truncated, inactive and tagged forms of staphylococcal HtrA proteins. The recombinant *htrA_{1r}* ORF (encoding HtrA₁-ΔTM-Ser₂₅₅Ala-His₆) was obtained as follows. (1) The 5' and the 3' regions of WT *htrA₁* gene were amplified by a high-fidelity *Taq* polymerase (FINNZYMME) using respectively the following primer couples (see Additional file 1: Table S1 for primer sequences): 1NFΔTM2 (with a *NsiI* site at its 5' end) and 1IRS > A (bearing a point mutation for Ser₂₅₅Ala substitution), or 1IFS > A (bearing a point mutation for Ser₂₅₅Ala substitution) and 1CRHIS (bearing a sequence encoding His₆ with a limited risk of ribosomal slippage, and bearing an *EcoRI* site at its 3' end). (2) Using a mix of both the resulting PCR fragments as a template, 1NFΔTM2 and 1CRHIS as primers and a high-fidelity A-tailing *Taq* polymerase (DNA Expand ROCHE), an overlap PCR fragment, *htrA_{1r}*, was obtained.

The recombinant *htrA_{2r}* ORF (encoding SP_{Exp4}-HtrA₂-ΔTM-Ser₆₁₉Ala-His₆) was obtained as follows. (1) The 5' and the 3' regions of WT *htrA₂* gene were amplified by a high-fidelity *Taq* polymerase (FINNZYMME) using respectively the following primer couples: either 2NFΔTM2 and 2IRS > A (bearing a point mutation for Ser₆₁₉Ala substitution), or 2IFS > A (bearing a point mutation for Ser₆₁₉Ala substitution) and 2CRHIS (bearing the sequence encoding His₆ tag and an *EcoRI* site). (2) Using a mix of both the resulting PCR fragments as a template, and 2NFΔTM2 and 2CRHIS primers, an ORF fragment (containing a *NsiI* site) was then obtained by high-fidelity overlap PCR. (3) An ES fragment encoding the expression and secretion system (P_{Zn} *zitR exp4_{SP}*) of pLB145 [4] was amplified using PznF and SPΔTM2R primers. Using a mix of ES and ORF fragments as a template and PznF and 2CRHIS primers, a high-fidelity overlap PCR was performed. Finally, using the resulting fragment as a template, ZitH2F and 2CRHIS primers and a A-tailing *Taq* polymerase (DNA Expand ROCHE), *htrA_{2r}* PCR fragment was obtained.

Each *htrA_{1r}* and *htrA_{2r}* PCR fragment was cloned into pGEM-T Easy Vector (Promega), according to the manufacturer's instructions. After transformation of highly competent JM109 cells, selection on ampicillin, X-Gal and IPTG, and screening for white colonies, recombinant plasmids were extracted, insert size was checked by PCR, and the inserts were sequenced. The resulting plasmids were respectively named pVE8124 and pVE8125 (Table 1B). *htrA_{1r}* and *htrA_{2r}* fragments were respectively recovered from pVE8124 or pVE8125 plasmids by *NsiI* + *EcoRI* or *BamHI* + *EcoRI* double digestions. They were subcloned into pLB145 [4] digested by the same

enzymes (Additional file 2: Figure S1). After transformation into strain MG1363, the resulting plasmids were checked by PCR and sequenced. The final plasmids were respectively named pVE8126 and pVE8127 (Table 1B).

Recombinant protein production in *L. lactis*

Recombinant lactococcal cells were grown in 5 mL of M17 medium (buffered by 88 mM β-glycerophosphate) supplemented by 1% glucose, overnight in tubes. For growth in flasks, an overnight culture was diluted 100-fold in 280 mL of the same medium in a flask, and let to grow at 30°C. For growth in fermenters at controlled pH, serial tenfold dilutions of an overnight culture were grown overnight in M17 medium supplemented by 2% glucose, and cultures still in the exponential phase (OD₆₀₀ between 0.4 and 0.7) were diluted 100-fold in 800 mL of preheated medium, either the same medium or a derivative, more strongly buffered, medium (176 mM β-glycerophosphate) to be grown in a fermenter (Biostat Q, Sartorius), at 30°C and at pH 6.5 (by addition of 5 N NaOH under shaking at 100 rpm).

When cultures reached an OD₆₀₀ of 0.5 (or in one case, 2), induction was achieved by adding 500 μM EDTA, and cultures were further incubated for 4 h (or for 2 h in the case of the culture induced at OD₆₀₀ 2). After centrifugation at low speed and at 4°C, supernatants were filtered on 0.22 μm, concentrated by about 25-fold by ultrafiltration (under a nitrogen pressure of less than 3 bars and at 4°C) using Millipore filters (Ultrafiltration Membranes NMWL 10,000), and stored at 4°C before purification.

Protein purification

Dry resin (His-Select Nickel Affinity Gel, Sigma; 1 mL) was washed on a Econo-Pac column (Chromatography Columns; BIO-RAD) with 5 volumes of water and 10 volumes of buffer A (50 mM NaH₂PO₄, 300 mM NaCl, 10 mM Imidazole (Sigma[®]); pH 8.0), incubated for 15 min at 4°C, equilibrated with 10 volumes of buffer A and incubated for a further 15 min at 4°C. In parallel, each supernatant was diluted twofold in an equal volume of buffer B (100 mM NaH₂PO₄, 600 mM NaCl, 20 mM imidazole at pH 8.0). Resin (1 mL) and treated supernatant were mixed. After incubation overnight at 4°C, the mix was loaded onto the column and washed twice with buffer A. After addition of 3 mL of buffer C [50 mM NaH₂PO₄, 300 mM NaCl, 250 mM imidazole (Sigma[®]); pH 8.0] repeated three times, the three elution fractions were pooled, concentrated nine- to tenfold by ultrafiltration (to reach a final volume of 1 mL), dialysed against PBS buffer overnight at 4°C with shaking (Slide-A-Lyser[®] Dialysis Cassette 0.5–3 mL/3,500 Da, Pierce[®]). Finally, glycerol was added to a final concentration of 10% before storage at −20°C. Protein concentration was determined

by the Bradford method (Bio-Rad Protein Assay) according to the manufacturer's instructions, using BSA (Protein Assay Standard II) as a standard. After each concentration or purification step, the protein fractions were analysed for protein purity and stability by Western blotting using antibodies against HtrA₁ [23] or His₆ (INVITROGEN).

Protein analysis by mass spectrometry

rHtrA proteins were loaded on precasted 4–12% Bis-Tris Mini Gels (Invitrogen, France), SDS-PAGE runs were performed, and gels were stained with Coomassie blue (BioRad, Marnes-la-Coquette, France). Bands of interest were excised and protein identification was performed as previously described [24] using PAPPISO platform facilities (Jouy-en-Josas, France; <http://pappiso.inra.fr>). Following SDS-PAGE migration and trypsinolysis, protein identification was performed querying MS/MS data against a in-house database containing rHtrA₁ and rHtrA₂ sequences (Additional file 3: Figure S2) together with the database for *L. lactis* subsp. *cremoris* strain MG1363 proteins (Uniprot, 2011/03/04; <http://www.uniprot.org/uniprot/?query=organism:mg1363&fil=organism:%22Lactococcus%20lactis%20subsp.%20cremoris%20%28strain%20MG1363%29%20%28%28%29%22&sort=score>) and a in-house contaminant protein database. The number of spectras attributed to each rHtrA protein was high, whereas no *L. lactis* protein could be detected.

Secondary structure analysis by circular dichroism

Synchrotron radiation circular dichroism experiments, covering the UV spectral range from 190 to 305 nm, were carried out at the DISCO beam line of the Synchrotron SOLEIL (Saint Aubin, France; <http://www.synchrotron-soleil.fr>). Spectra were acquired at different temperatures, progressively increasing by 5°C in the 25–95°C range. CaF₂ (Calcium Fluoride) 50 µm optical pathlength cells were loaded with 2 µL of each protein (rHtrA₁ or rHtrA₂) in a 50 mM Tris HCl (pH 7.5) and 50 mM NaCl buffer to reach a final protein concentration of 1 mg/mL. For each temperature curve, the mean of three spectra (acquired at 1 nm step per second between 190 and 305 nm) was calculated before subtraction of the baseline (by buffer subtraction) and set to zero between 255 and 260 nm. Mean spectra were calibrated to a standard solution of (+)-camphor-10-sulphonic acid (CSA), normalized and converted to Δε (molar circular dichroism, M⁻¹ cm⁻¹) using the software *CDtool* [60]. The thermal denaturation curve of each rHtrA protein was calculated at 207 nm, and the melting temperature (T_m) was determined from a sigmoidal fit. Spectra were represented using Origin software (OriginLab, Northampton, MA, USA).

Size exclusion chromatography coupled to multi angle light scattering

Purified rHtrA₁ or rHtrA₂ proteins (30 µL of samples at 1–4 mg/mL) were loaded on a KW-803 column (Shodex) equilibrated in PBS buffer at a 0.5 mL/min flow rate (Shimadzu HPLC system). Detection was performed using a MiniDAWN TREOS multi angle light scattering detector and an Optilab T-rEX differential refractometer (Wyatt Technology). Molar mass was calculated with the Astra 6.1.1.17 software, using a differential index of refraction (dn/dc) value of 0.183 mL/g.

Protein folding assays

First, the refolding of two proteins, citrate synthase and α-glucosidase, was followed. Denaturation and renaturation reactions were carried out at 20°C. For both proteins, renaturation was initiated by pouring the renaturation solvent onto the unfolded protein under vortex agitation in Eppendorf polyethylene tubes. Citrate synthase was denatured at a concentration of 10 µM in 8 M urea, 50 mM Tris, 2 mM EDTA, 20 mM dithiothreitol pH 8.0 for 30 min. Renaturation was initiated by a 100-fold dilution in 40 mM Hepes, 50 mM KCl, 10 mM (NH₄)₂SO₄, 2 mM potassium acetate, pH 8.0, in the absence of added protein or in the presence of DnaK, rHtrA₁ or rHtrA₂. The enzymatic activity of citrate synthase was measured as described previously [61]. α-Glucosidase was denatured at a concentration of 2 µM in 8 M urea, 0.1 M potassium phosphate, 1 mM EDTA, 20 mM dithiothreitol, pH 7.0 for 5–10 min. Renaturation was initiated by a 30-fold dilution in 40 mM Hepes–KOH, pH 7.8 at 20°C. The enzymatic activity of α-glucosidase was measured as described previously [61]. Concentrations of substrate proteins and chaperones were similar to those used by us [61] and others [62] for investigating chaperone activities of GroEL and thioredoxin. Pig heart citrate synthase and *Saccharomyces cerevisiae* α-glucosidase were from Sigma. DnaK was purified as described in [61].

Second, the thermal aggregation of citrate synthase was followed. The native enzyme (80 µM) was diluted 100-fold in 40 mM Hepes, 50 mM KCl, 10 mM (NH₄)₂SO₄, 2 mM potassium acetate, pH 8.0, at 44°C, in the absence of added proteins, or in the presence of DnaK, rHtrA₁ or rHtrA₂. Citrate synthase aggregation was monitored by measuring the absorbance at 650 nm as described in [63].

Immunization of mice and Western blotting

OF1 mice were immunized with 10 µg of rHtrA₁ or rHtrA₂ co-injected with SP02 adjuvant (proprietary adjuvant of Sanofi Pasteur) by the subcutaneous route (0.2 mL) in the scapular girdle region at day 0, day 21 and day 36. Blood samples were collected under anaesthesia (see above) at day 0 and at day 61 at the retro-orbital sinus.

Staphylococcal culture pellets were lysed according to optical density. An equivalent of $OD_{680nm} = 20$ was lysed, for each pellet, in 250 μ L of 2X lysis buffer: Tris-HCl 20 mM, Triton 1.2%, PMSF 1 mM, Halt Protease Inhibitor Single-Use Cocktail (Thermo Scientific) 1X, benzonase (Sigma) 5 U/ μ L and lysostaphin (Sigma) 100 μ g/ μ L and incubated over night at 37°C. This suspension was heat inactivated 15 min at 95°C.

Samples were resolved by SDS 4–12%-PAGE (NuPAGE, Invitrogen) and transferred to nitrocellulose membranes (Transblot Transfert Medium, BioRad). Membranes were saturated with 5% skim milk in PBS buffer (2.7 mM KCl, 137 mM NaCl) overnight at 4°C. Filters were then incubated with 1:200 dilution of the primary antibody in 1% skim milk in PBS buffer for 1 h at room temperature, washed three times for 5 min with PBS with 0.05% Tween 20 (PBST). Filters were then incubated with 1:3,000 dilution of a Peroxidase AffiniPure F(ab')₂ fragment goat anti-mouse IgG (H + L) (Jackson ImmunoResearch Laboratories, USA) with 1% skim milk in PBS buffer for 1 h at room temperature and washed three times for 5 min as described above. Finally, the filters were washed 10 min in deionized water. Immunopositive bands were visualized using the Amplified Opti-4CN Kit (Bio-Rad Laboratories, Inc., USA) and were quantified using a densitometer (Genetools, Syngene, UK).

Flow cytometry assay

The ability of polyclonal antisera elicited by the recombinant proteins to bind to the surface of live *S. aureus* strains was determined using flow cytometric detection of indirect fluorescence. Strain Lowenstein was grown at 37°C with shaking. Frozen bacteria were inoculated into 50 mL of appropriate medium and grown till exponential, late exponential or late stationary phases. A culture sample was centrifuged and washed once with PBS (Eurobio, Courtaboeuf, France). The final pellet was resuspended in PBS with 1% bovine serum albumin (BSA, Eurobio, Courtaboeuf, France) at a density of 10^8 CFU/mL. 20 μ L of dilutions of pooled serum were added to 20 μ L of bacteria in 96 deep-well plates (Ritter, Schwabmunchen, Germany). For each serum, three dilutions were tested: 1/200, 1/2,000 and 1/20,000. The plate was incubated for 1 h at 37°C with shaking. The bacteria were centrifuged, washed once with PBS 1% BSA and resuspended with 100 μ L of goat anti-mouse IgG F(ab')₂ conjugated to PE (Southern Biotech, Birmingham, USA) diluted 100-fold. The plate was incubated for 1 h at 37°C with shaking in the dark. The bacteria were washed twice with PBS 1% BSA. The fluorescent staining of bacteria was analyzed on a Cytomics FC500 flow cytometer (Beckman Coulter, Fullerton, USA). The fluorescent signal obtained for bacteria incubated with the specific polyclonal antisera

was compared to the signal obtained for bacteria incubated with the corresponding negative control serum (buffer + SP02 adjuvant alone).

Results and discussion

Design of recombinant staphylococcal HtrA proteins

In *S. aureus*, there are two transmembrane members of the HtrA family, HtrA₁ and HtrA₂ [23, 57] (for example in strain COL: Q5HF46 and Q5HH63, and data not shown for other published genomes; here, we provide the sequence of *htrA* genes from the clinical strain Lowenstein: Genbank BankIt1643789 htrA1_LOW KF322112 and BankIt1643789 htrA2_LOW KF322111) which are highly conserved between strains (more than 95 or 61% identity respectively). Even though HtrA₂ bears a large N-terminal domain of unknown function [23], both HtrA₁ and HtrA₂ proteins display the typical family architecture [25, 26] (Figure 1) with three regions: from their N- to C-terminus, (1) a transmembrane domain as the export signal, (2) a catalytic domain with a characteristic His Asp Ser triad (His₁₄₄, Asp₁₇₄ and Ser₂₅₅ in the case of HtrA₁, and His₅₀₄, Asp₅₃₄ and Ser₆₁₉ in the case of HtrA₂) and (3) one PDZ domain (a protein-protein interaction domain named for the three proteins (PSD95, DLG1, and ZO-1) where it was initially discovered [26]). In both staphylococcal HtrA proteins, like in other family members of Gram-positive species, the C-terminal region encompassing the catalytic and PDZ domains is predicted to be extra-cellular (predicted C-out topology by HMMTOP, <http://www.enzim.hu/hmmtop/html/submit.html>).

For each HtrA protein of the staphylococcal strain COL, a soluble, proteolytically inactive and tagged form was produced (see Additional file 3: Figure S2). (1) The soluble, C-terminal region (devoid of the transmembrane domain, Figure 1) was fused in frame to a lactococcal signal peptide (see below, [4]) to be produced as a secreted protein. (2) The conserved catalytic Ser residue (Ser₂₅₅ or Ser₆₁₉ in the case of HtrA₁ or HtrA₂ respectively) was replaced by an Ala residue to abolish proteolytic activity, and thus to avoid the self-degradation previously observed for WT proteins when overproduced in a lactococcal *htrA* mutant strain [23]. (3) A His₆ tag was fused at the C-terminus of each recombinant protein to facilitate its purification.

To delete the N-terminal transmembrane domain of each HtrA protein without affecting the overall protein folding, we exploited the strategy previously applied to produce a recombinant, soluble form of the *E. coli* transmembrane protein DegS (sharing 31% identity with each of the staphylococcal HtrA proteins) whose structure could be solved [64]. The precise boundary of the deletion in the staphylococcal HtrA proteins was chosen to preserve, upstream of the region homologous to recombinant DegS (Figure 1), an N-terminal negatively charged




Figure 1 Architecture of staphylococcal HtrA proteins and design of soluble proteins. Three HtrA family members are shown: from *top to bottom*, *E. coli* DegS, *S. aureus* HtrA₁ and HtrA₂ proteins (strain COL). They display the typical domain organisation of the family: transmembrane, catalytic and PDZ domains are shown as hatched, *dark grey* and *light grey* boxes respectively, with their boundaries (residue position) indicated below. The catalytic Serine residue (S, in *bold*) is shown. The recombinant DegS form whose structure has been solved after N-terminal transmembrane domain deletion [64] is named DegSΔTM. A similar deletion strategy was applied to HtrA₁ and HtrA₂ proteins leading to N-terminally truncated proteins named HtrA₁ΔTM and HtrA₂ΔTM. All truncated protein forms are shown as *lines* with the position of their first and last residues in the corresponding WT sequence indicated.

residue to contribute to the negative charge at the N-terminus of the mature secreted rHtrA protein (see below).

Lactococcal system for protein production and secretion

For protein production and secretion in *L. lactis*, we chose to clone the recombinant ORFs in pLB145, a lactococcal expression and secretion vector [4]. In the resulting plasmids (Additional file 2: Figure S1), recombinant ORFs are under the control of the lactococcal ZitR-regulated P_{zit} promoter [11, 19] so that their expression can be induced by the addition of EDTA [4, 11]. They are fused in frame to the coding sequence of the lactococcal signal peptide SP_{Exp4} (bearing two positively charged residues at its N-terminus) plus the two negatively charged residues present at its C-terminus in the endogenous mature Exp4 protein [4, 20]. This fusion strategy preserves both the natural charges around SP_{Exp4} to ensure its correct insertion into the membrane (according to the positive-inside rule [65, 66]), and its natural cleavage site for the lactococcal signal peptide peptidase. Finally, this fusion strategy should ensure efficient secretion both at the translocation and release steps.

Production and secretion of recombinant proteins in *L. lactis*, and purification

The efficiency of recombinant protein production and secretion in an *L. lactis* WT strain (strain MG1363) was followed. After growth of the recombinant strains (bearing the recombinant pLB145-derived plasmids pVE8126 and pVE8127) in a rich medium up to the exponential growth phase and induction by EDTA addition, the culture supernatants were found to contain, in similar






Figure 2 Production of secreted rHtrA proteins in *L. lactis*. rHtrA₁ and rHtrA₂ proteins, together with a recombinant form of the staphylococcal nuclease [4] as a positive control, were produced and secreted in *L. lactis*. Recombinant strains [MG1363(pLB145) in lanes 1 and 2, MG1363(pVE8126) in lane 3 and MG1363 (pVE8127) in lane 4] were grown to the exponential phase in rich M17 medium supplemented with glucose and buffered with β -glycerophosphate, in flasks. EDTA at 500 μ M was added to the cultures to induce (lanes 2–4) or not (lane 1, as a negative control) recombinant protein production. After further growth, culture supernatants were recovered, concentrated, precipitated and finally subjected to SDS-PAGE and Coomassie Brilliant Blue staining. Culture supernatants all show the major lactococcal secreted protein, Usp45 [9] either alone (lane 1) or together with one of the recombinant proteins (lanes 2–4). Usp45 (lanes 1–4), rHtrA₁ (lane 3), rHtrA₂ (lane 4) and for recombinant staphylococcal nuclease (lane 2), both the secreted form, NucB, and its maturation product (released by lactococcal HtrA protease), NucA [4, 10], are indicated by arrows.

amounts as the major lactococcal secreted protein, Usp45 [9], an additional protein of the expected size (Figure 2), which could specifically be recognized by anti-HtrA₁ [23]



or anti-His₆ antibodies (data not shown). Each secreted recombinant rHtrA protein was found to be stable in the culture supernatant of the otherwise WT host strain (Figures 2, 3 and 4a, lane 1 and Figure 4b, lane 1). This result is interesting in two ways. First, as the proteolytic activity and self-degradation ability of staphylococcal WT HtrA proteins are supported by several lines of evidence [23, 57], the stability of substituted rHtrA(Ser-Ala) proteins strongly suggests that the mutation of the main catalytic residue leads to protease inactivation, as expected. Second, as many heterologous and/or recombinant proteins are degraded by the endogenous HtrA protease in a lactococcal WT background [4, 10, 22], here, the resistance of rHtrA proteins to this endogenous protease strongly suggests that their translocation across the cytoplasmic membrane is efficient and quick, without accumulation of unfolded and degradation-prone intermediates. Our carefully designed protein fusion strategy (see above) therefore proved to create secretion-prone precursors that were translocated and released without being degraded. Carefully designed secretion in *L. lactis* can provide stable proteins and preclude the use of an *htrA* mutant devoid of surface proteolytic activity as the host strain although in some cases, probably depending on the induction level and/or on the intrinsic folding ability of the protein, this use can turn out to be necessary (for



example the *Staphylococcus hyicus* WT lipase, a naturally secreted protein, is extensively degraded in *L. lactis* except in an *htrA* mutant [4]).

Growth conditions were then optimized to increase biomass and thus protein yield (Figure 3). Lactococcal recombinant strains were grown in fermenters at controlled pH. The rich medium used for lactococcal culture was optimized by increasing the concentration of glucose and β -glycerophosphate buffer in order to prevent bacterial lysis due to glucose starvation (data not shown, and Pascal Loubière, INRA Toulouse, personal communication) and to decrease the need for NaOH addition to control the pH, respectively. After EDTA induction in exponentially growing cultures, the recombinant proteins were secreted in higher amounts when recombinant

lactococcal cells were grown in fermenters rather than in flasks [for rHtrA₁, compare lane 3 and lane 1 in Figure 3, and for both rHtrA₁ and rHtrA₂ proteins, compare their relative amounts using Usp45 protein as a standard between Figures 2 and 4: in contrast to the situation after growth in flasks (Figure 2 lane 3 for rHtrA₁ and lane 4 for rHtrA₂), each rHtrA protein became the major secreted protein in fermenters (Figure 4a, lane 1 for rHtrA₁ and Figure 4b, lane 1 for rHtrA₂)]. In fermenters, a highly buffered medium further improved secretion efficiency (for rHtrA₁, compare lane 1 and lane 2 in Figure 2, and data not shown for rHtrA₂). Finally, for rHtrA protein production, recombinant lactococcal strains were grown in small-scale fermenters and rHtrA proteins were purified by chromatography affinity from the culture supernatants (Figure 4), concentrated, dialyzed and quantified by Bradford analysis. Using the optimized medium, protein yields were 2.5 and 2.2 mg/L for rHtrA₁ and rHtrA₂ respectively, and in total, about 7 mg of each protein could be obtained. The identity of purified rHtrA proteins was confirmed by trypsinolysis followed by mass spectrometry (Table 2). *L. lactis* thus proved to be an efficient cell factory to produce the soluble C-terminal region of trans-membrane HtrA proteins as secreted and stable forms (even after conservation at −20°C; data not shown).


rHtrA proteins are correctly folded

In order to characterize the secondary structure of purified rHtrA proteins, they were studied by synchrotron radiation circular dichroism (SRCD) spectroscopy at different temperatures (Figure 5). CD profiles of both proteins are similar to each other, and the protein secondary structures are probably mainly random coil (see minima around 202–205 nm in Figure 5) and some beta sheet (see shoulder around 215 nm in Figure 5), as expected for HtrA family members [67] and as previously described for another recombinant HtrA protein [68]. Staphylococcal rHtrA proteins share similar CD profiles with other recombinant HtrA proteins, in particular with an N-terminally truncated and inactive form of the periplasmic HtrA protein from *Haemophilus influenzae* [68], and, to a smaller extent, with a truncated, soluble form of the mitochondrial transmembrane HtrA2-Omi protein (after transmembrane domain

Table 2 rHtrA protein identity


Description	Coverage (%)	Spectra	Unique peptides	log(E value)
rHtrA ₁	64	129	30	−157
rHtrA ₂	80	235	45	−298

Purified rHtrA proteins were submitted to trypsinolysis and mass spectrometry, and the results are shown.



deletion) [69]. The secondary structure profile of rHtrA proteins did not display any significant change between 25 and 45°C, indicating that they are folded under these conditions. Thermal denaturation and loss of secondary structure was observed above 60°C for rHtrA₁ [melting temperature (T_m): 62.1°C ± 1.3 Figure 5a inset] and above 55°C for rHtrA₂ (T_m: 55.5°C ± 1.4 Figure 5b inset). Similar results were previously obtained for recombinant HtrA proteins from *H. influenzae* [68] and *E. coli* [70].

Protein oligomeric status was then studied by size exclusion chromatography coupled to multi angle light scattering (SEC-MALS, at three different protein concentrations, Figure 6). They were found to be mainly monomeric in solution, in contrast to all other family members, known to be organized at least as homotrimers, both in



solution and as crystals (see [64] for an example) or even, for some of them, as large size multimers of homotrimers [26]. Further studies will be needed to establish whether staphylococcal proteins are unable to trimerize.

rHtrA proteins are active chaperones

The chaperone activity of both recombinant proteins was then tested as many HtrA proteins are dual proteins displaying both proteolytic and folding activities [25, 27], and as their chaperone activity can be demonstrated when their catalytic Serine residue is substituted to an Alanine [71]. We first examined the renaturation of urea-unfolded α -glucosidase in the presence of purified rHtrA₁ and rHtrA₂. Maximal recovery of α -glucosidase activity was 9% in the absence of chaperone, 21% in the presence of 5 μ M rHtrA₁, 22% in the presence of 5 μ M rHtrA₂, and 23% in the presence of 5 μ M DnaK (Figure 7a) as a positive control [61]. We also investigated the renaturation of urea-unfolded citrate synthase in the presence of rHtrA₁ and rHtrA₂. The maximal recovery of citrate synthase activity was 8% in the absence of chaperone, 12% in the presence of 5 μ M rHtrA₁, 13% in the presence of 5 μ M rHtrA₂ and 18% in the presence of 5 μ M DnaK (not shown). On the contrary, as previously reported [72], ovalbumin and lysozyme were unable to stimulate the renaturation of either citrate synthase or α -glucosidase (not shown). Thus, both rHtrA₁ and rHtrA₂ increased the productive folding of urea-denatured α -glucosidase and citrate synthase.

We then investigated the function of rHtrA₁ and rHtrA₂ under heat shock conditions. As reported previously [63, 72], citrate synthase loses its native conformation and undergoes aggregation during incubation

at 44°C. As shown in Figure 7b, 5 μ M rHtrA₁ or 5 μ M rHtrA₂ reduced citrate synthase aggregation by 30%, whereas 5 μ M DnaK reduced citrate synthase aggregation by 49%. On the contrary, ovalbumin and lysozyme, as previously reported [72], were inefficient in protecting citrate synthase from thermal denaturation (not shown). These results suggest that rHtrA₁ and rHtrA₂ can interact with partially unfolded proteins and protect them against thermal denaturation.

Together, these results demonstrate for the first time that the soluble domains of staphylococcal HtrA proteins possess chaperone activity in vitro. This activity is in the case of HtrA₂ protein independent of the long, N-terminal domain of unknown function [23], at least in vitro, and further studies will be needed to determine if this domain could contribute to envelope protein folding in *S. aureus* and/or to virulence in vivo. Finally, our results indicate that rHtrA proteins are correctly folded, and thus strongly suggest that they should expose conformational epitopes relevant for vaccine applications.

Purified rHtrA proteins are immunogenic in mice and WT HtrA₁ protein is exposed at the staphylococcal cell surface

WT HtrA proteins were then characterized to get insights on their expression and localization in staphylococcal cells. After injection of folded rHtrA₁ or rHtrA₂ protein in mice in the presence of an adjuvant (SP02, a proprietary adjuvant of Sanofi Pasteur), sera with high (>5 Log) IgG1 and IgG2a titers could be obtained, indicating that rHtrA proteins are immunogenic. The specificity of the raised polyclonal antibodies was demonstrated by Western blot analysis of cellular extracts from staphylococcal *htrA* mutant strains grown to the exponential phase (Figure 8a, b).




Figure 7 Chaperone properties of rHtrA proteins. **a** Refolding of urea-denatured α -glucosidase in the presence of rHtrA₁ or rHtrA₂. α -Glucosidase was denatured in urea and then renatured for 20 min by dilution of the denaturant as described under "Methods," at a concentration of 0.07 μ M in the absence of additional protein and in the presence of either 5 μ M rHtrA₁, 5 μ M rHtrA₂ or 5 μ M DnaK. **b** Thermal aggregation of citrate synthase in the presence of rHtrA₁ or rHtrA₂. The kinetics of citrate synthase aggregation was determined by light scattering at 650 nm. Native citrate synthase was diluted to a final concentration of 0.8 μ M at 44°C, as described under "Methods," in the absence of additional protein (circles), or in the presence of 5 μ M rHtrA₁ (triangles), 5 μ M rHtrA₂ (squares) or 5 μ M DnaK (crosses).




Figure 8 Expression of WT HtrA proteins in *S. aureus*. Immunoblot analysis using polyclonal anti-rHtrA₁ (**a**, **b**) or anti-rHtrA₂ (**c**, **d**) sera was performed on cell lysates of different *S. aureus* strains: each *htrA* mutants of strain COL (designated as COL *htrA*₁ and COL *htrA*₂ [57], **a**, **b**) and WT strain Lowenstein (**c**, **d**). All strains were grown in two media (TSB, SATA-2) and in the first line, under two different conditions (TSB, TSB + dipyrindyl corresponding to the addition of chelator), till different growth phases: the exponential phase (2 h) for *htrA* mutants of strain COL (**a**, **b**) and, for WT strain Lowenstein (**c**, **d**), the exponential (2 h), early stationary (6 h) and late stationary (24 h) phases. HtrA₁ was found to be completely stable (**a**, **c**), whereas HtrA₂ protein underwent a limited proteolysis giving rise to one minor degradation product of high molecular weight in the cells (**b**, **d**), as confirmed by the absence of proteolytic products in culture supernatants. *S. aureus* HtrA₁ and HtrA₂ thus behave differently from *Bacillus subtilis* HtrA (YkdA) protein (YkdA) which is known to be released into the supernatant as a processed form, devoid of its transmembrane domain [73].

These antibodies were then used to study the expression and cell surface localization of HtrA proteins in *S. aureus* after growth under different conditions. In a preliminary experiment, expression was studied in two strains (strain COL and strain Lowenstein which is responsible for systemic infections) grown in two media: a defined medium (containing a high salt concentration), and a complex standard medium supplemented or not with 2,2'-Dipyridyl (a chelator leading to iron depletion) as high salt concentration and iron depletion are close

to the conditions faced by *S. aureus* in the host. Western blotting allowed detecting full-length HtrA₁ and HtrA₂ proteins in the cells in similar amounts under all conditions (Figure 8), indicating a constitutive expression under the tested conditions and the absence of extensive degradation, as confirmed by the analysis of culture supernatants (data not shown).

Finally, the exposure of the HtrA protein C-terminal region at the staphylococcal cell surface in strain Lowenstein was tested by cytometry analysis using




Figure 9 Cytometry analysis of WT HtrA protein exposure at the staphylococcal cell surface. The cell surface exposure of WT HtrA₁ (**A**) and HtrA₂ (**B**) proteins from strain Lowenstein was analyzed by flow cytometry. Staphylococcal cells were grown either in TSB medium (**a**), TSB supplemented with 2,2' Dipyridyl 1 mM (**b**), or SATA-2 medium (**c**) till early exponential phase, late exponential phase or late stationary phase. Shaded and white areas represent cells incubated with antibodies against SP02 adjuvant or each rHtrA protein (rHtrA₁ in **A** and rHtrA₂ in **B**) respectively.

the mice polyclonal antibodies. In staphylococcal cells grown in the complex medium (supplemented or not with 2,2' Dipyridyl), HtrA₁ protein could be detected at the cell surface (Figure 9A) confirming its predicted topology and the cell surface exposure of its C-terminal region, in agreement with our previous demonstration of its extra-cellular proteolytic activity [23]. On the contrary, HtrA₂, although produced under the same growth conditions (Figure 8D), was not accessible to antibodies added from the medium (Figure 9B), suggesting that the HtrA₂ C-terminal region might remain embedded in the staphylococcal cell wall. These results suggest that, in the perspective of vaccine development, rHtrA₁ protein might be a better candidate than rHtrA₂ protein, even though further studies will be needed to study their expression and antigenicity in vivo in the host.

Conclusions

In this study, the C-terminal region of staphylococcal HtrA transmembrane proteins could efficiently be produced and secreted in *L. lactis* as correctly folded and stable forms that were easily purified from the culture medium in one step. *L. lactis* was demonstrated to be an efficient cell factory with respect to protein quality, in terms of both purity and folding, in particular in the case of a surface-exposed antigen, like staphylococcal HtrA₁ protein. Our results indicate that to produce proteins of high quality and purity for medical applications, *L. lactis*

is an efficient and competitive alternative to *E. coli* and *B. subtilis* hosts.

Additional files

Additional file 1: Table S1. Primers used in this study

Additional file 2: Figure S1. Plasmids used for the production and secretion of rHtrA proteins. Plasmids pVE8126 (on the left) and pVE8127 (on the right) for the production and secretion rHtrA proteins were constructed by cloning recombinant *htrA_{1r}* (on the left) and *htrA_{2r}* (on the right) ORFs into pLB145: *htrA_{1r}* was cloned in place of *nuc* by *Nsi*I and *Eco*RI double digestion, whereas *htrA_{2r}* was cloned in place of *exp4_{sp}-nuc* by *Bam*HI and *Eco*RI double digestion. The proteins encoded by each *htrA_r* ORF are represented down below. For both of them, the catalytic and PDZ domains, together with the His₆-tag are shown as dark grey, light grey and black boxes respectively, with their boundaries indicated, and the Alanine (A) substituting the catalytic residue is also indicated in bold with its position. Whereas *htrA_{2r}* ORF encodes the entire protein precursor with SP_{Exp4} signal peptide (horizontally hatched box), *htrA_{1r}* is fused in frame to *exp4_{sp}* (encoding SP_{Exp4}) by cloning, leading to the *exp4_{sp}-htrA_{1r}* fusion encoding the protein precursor.

Additional file 3: Figure S2. rHtrA protein sequence. rHtrA proteins (rHtrA1 in panel A and rHtrA2 in panel B) are the mature secreted forms of hybrid precursors after the cleavage of lactococcal SP_{Exp4} signal-peptide (MKKINLALLTLATLMGVSS AVVFA) [20]. Both rHtrA proteins retain at their N-terminus, the first two negatively charged residues of mature secreted Exp4 form (in blue). At their C-terminus, they both bear a His₆ tag (in brown). In both of them, the catalytic residue (Serine 255 in HtrA₁ and Serine 619 in HtrA₂) has been substituted to an Alanine residue (in red). N-terminally truncated HtrA proteins (after transmembrane deletion) are shown in black: in A, HtrA₁ΔTM is HtrA₁ (Q5HF46) starting at Aspartate 60 and in B, HtrA₂ΔTM is HtrA₂ (Q5HH63) starting at Aspartate 441 (see Figure 1).

Authors' contributions

FS designed and performed all experiments for recombinant rHtrA protein production in *L. lactis* under the supervision of IP, FT and DS, under the supervision of BR, carried out Western blotting and flow cytometry experiments. DC performed MS/MS experiments. CV and PF were in charge of SRCD and SEC-MALS analysis. VG performed chaperone activity tests under the supervision of GR, BR, PF, DC and GR wrote the relevant sections of the manuscript they were involved in. IP conceived and supervised the whole project and wrote the manuscript. All authors read and approved the final manuscript.

Author details

¹ INRA, UMR1319 Micalis (Microbiologie de l'Alimentation au service de la Santé), Domaine de Vilvert, 78352 Jouy-en-Josas Cedex, France. ² Present Address: Institut Curie/CNRS, UMR3244, 25 rue d'Ulm, 75248 Paris Cedex 05, France. ³ Sanofi Pasteur, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. ⁴ Stress molecules, Institut Jacques Monod, Université Paris 7, 15 rue Hélène Brion, 75013 Paris, France. ⁵ CNRS, Avenue de la Terrasse, Bât. 34, 91190 Gif-Sur-Yvette, France. ⁶ Present Address: LPBA, Institut Pasteur, Bât. Calmette, 75015 Paris, France.

Acknowledgements

This work benefited from the facilities and expertise of the Imagif Structural and Proteomic Biology Pole of the Centre de Recherche de Gif (<https://www.imagif.cnrs.fr>) biophysics platform. We thank Sophie Ruiz (Sanofi Pasteur) for her participation in this study, Vincent Juillard (Micalis, Jouy-en-Josas) and Mireille Yvon (Micalis, Jouy-en-Josas) for their help in ultracentrifugation and fermenter experiments respectively. Thanks to Maarten van de Guchte (Micalis, Jouy-en-Josas) for critical reading of the manuscript.

Competing interests

INRA is a government research organism that has two patents on protein production by *L. lactis*: i) Zinc-regulated prokaryotic expression cassettes: US 8,354,272 B2, CA 2496350, EP 1537215 B1 and WO 2004/020640; and ii) Gram-positive bacteria deprived of HtrA protease activity and their uses: US 6,994,997 B1, EP 1141337 B1 and WO 2000/039309. Bachra Rockbi, Delphine Seguin and Fabienne Telles are employees of Sanofi Pasteur an international pharmaceutical company, notably involved in vaccine development. Sanofi Pasteur has a patent: Method for the Production of Overproducing *Staphylococcus aureus* Strains, US20100880566 20100913.

Received: 9 January 2015 Accepted: 8 May 2015

Published online: 16 July 2015

References

- Corchero JL, Gasser B, Resina D, Smith W, Parrilli E, Vazquez F et al (2013) Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. *Biotechnol Adv* 31:140–153
- Garcia-Fruitos E (2012) Lactic acid bacteria: a promising alternative for recombinant protein production. *Microb Cell Fact* 11:157
- Lee SY, Mattanovich D, Villaverde A (2012) Systems metabolic engineering, industrial biotechnology and microbial cell factories. *Microb Cell Fact* 11:156
- Morello E, Bermudez-Humaran LG, Llull D, Sole V, Miraglio N, Langella P (2008) *Lactococcus lactis*, an efficient cell factory for recombinant protein production and secretion. *J Mol Microbiol Biotechnol* 14:48–58
- Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermudez-Humaran LG et al (2005) Protein secretion in *Lactococcus lactis*: an efficient way to increase the overall heterologous protein production. *Microb Cell Fact* 4:2
- Sevastyanovich YR, Alfasi SN, Cole JA (2010) Sense and nonsense from a systems biology approach to microbial recombinant protein production. *Biotechnol Appl Biochem* 55:9–28
- Casalta E, Montel MC (2008) Safety assessment of dairy microorganisms: the *Lactococcus* genus. *Int J Food Microbiol* 126:271–273
- Chen RH, Huang CJ, Newton BS, Ritter G, Old LJ, Batt CA (2009) Factors affecting endotoxin removal from recombinant therapeutic proteins by anion exchange chromatography. *Protein Expr Purif* 64:76–81
- van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM, Simons G (1990) Cloning of *usp45*, a gene encoding a secreted protein from *Lactococcus lactis* subsp. *lactis* MG1363. *Gene* 95:155–160
- Poquet I, Saint V, Seznec E, Simoes N, Bolotin A, Gruss A (2000) HtrA is the unique surface housekeeping protease in *Lactococcus lactis* and is required for natural protein processing. *Mol Microbiol* 35:1042–1051
- Llull D, Poquet I (2004) New expression system tightly controlled by zinc availability in *Lactococcus lactis*. *Appl Environ Microbiol* 70:5398–5406
- Madsen SM, Arnau J, Vrang A, Givskov M, Israelsen H (1999) Molecular characterization of the pH-inducible and growth phase-dependent promoter P170 of *Lactococcus lactis*. *Mol Microbiol* 32:75–87
- Mierau I, Kleerebezem M (2005) 10 years of the nisin-controlled gene expression system (NICE) in *Lactococcus lactis*. *Appl Microbiol Biotechnol* 68:705–717
- Ng DT, Sarkar CA (2013) Engineering signal peptides for enhanced protein secretion from *Lactococcus lactis*. *Appl Environ Microbiol* 79:347–356
- Ravn P, Arnau J, Madsen SM, Vrang A, Israelsen H (2003) Optimization of signal peptide SP310 for heterologous protein production in *Lactococcus lactis*. *Microbiology* 149:2193–2201
- Glenting J, Poulsen LK, Kato K, Madsen SM, Frokiaer H, Wendt C et al (2007) Production of recombinant peanut allergen Ara h 2 using *Lactococcus lactis*. *Microb Cell Fact* 6:28
- Bermudez-Humaran LG, Langella P, Commissaire J, Gilbert S, Le Loir Y, L'Haridon R et al (2003) Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in *Lactococcus lactis*. *FEMS Microbiol Lett* 224:307–313
- Neef J, Koedijk DG, Bosma T, van Dijk JM, Buist G (2014) Efficient production of secreted staphylococcal antigens in a non-lysing and proteolytically reduced *Lactococcus lactis* strain. *Appl Microbiol Biotechnol* 98:10131–10141
- Llull D, Son O, Blanie S, Briffotiaux J, Morello E, Rogniaux H et al (2011) *Lactococcus lactis* ZitR is a zinc responsive repressor active in low, non-toxic zinc concentrations in vivo. *J Bacteriol* 193:1919–1929
- Poquet I, Ehrlich SD, Gruss A (1998) An export-specific reporter designed for Gram-positive bacteria: application to *Lactococcus lactis*. *J Bacteriol* 180:1904–1912
- Tremillon N, Issaly N, Mozo J, Duvignau T, Ginisty H, Devic E et al (2010) Production and purification of staphylococcal nuclease in *Lactococcus lactis* using a new expression-secretion system and a pH-regulated mini-reactor. *Microb Cell Fact* 9:37
- Miyoshi A, Poquet I, Azevedo V, Commissaire J, Bermudez-Humaran L, Domakova E et al (2002) Controlled production of stable heterologous proteins in *Lactococcus lactis*. *Appl Environ Microbiol* 68:3141–3146
- Rigoulay C, Poquet I, Madsen SM, Gruss A (2004) Expression of the *Staphylococcus aureus* surface proteins HtrA1 and HtrA2 in *Lactococcus lactis*. *FEMS Microbiol Lett* 237:279–288
- Tremillon N, Morello E, Llull D, Mazmouz R, Gratadoux JJ, Guillot A et al (2012) PpiA, a surface PPIase of the cyclophilin family in *Lactococcus lactis*. *PLoS One* 7:e33516
- Clausen T, Kaiser M, Huber R, Ehrmann M (2011) HTRA proteases: regulated proteolysis in protein quality control. *Nat Rev Mol Cell Biol* 12:152–162
- Hansen G, Hilgenfeld R (2013) Architecture and regulation of HtrA-family proteins involved in protein quality control and stress response. *Cell Mol Life Sci* 70:761–775
- Merdanovic M, Clausen T, Kaiser M, Huber R, Ehrmann M (2011) Protein quality control in the bacterial periplasm. *Annu Rev Microbiol* 65:149–168
- Lipinska B, Fayet O, Baird L, Georgopoulos C (1989) Identification, characterization, and mapping of the *Escherichia coli* *htrA* gene, whose product is essential for bacterial growth only at elevated temperatures. *J Bacteriol* 171:1574–1584
- Strauch KL, Johnson K, Beckwith J (1989) Characterization of *degP*, a gene required for proteolysis in the cell envelope and essential for growth of *Escherichia coli* at high temperature. *J Bacteriol* 171:2689–2696
- Johnson K, Charles I, Dougan G, Pickard D, O'Gaora P, Costa G et al (1991) The role of a stress-response protein in *Salmonella typhimurium* virulence. *Mol Microbiol* 5:401–407
- Ingmer H, Brondsted L (2009) Proteases in bacterial pathogenesis. *Res Microbiol* 160:704–710

32. Foucaud-Scheunemann C, Poquet I (2003) HtrA is a key factor in the response to specific stress conditions in *Lactococcus lactis*. *FEMS Microbiol Lett* 224:53–59
33. Chitlaru T, Zaide G, Ehrlich S, Inbar I, Cohen O, Shafferman A (2011) HtrA is a major virulence determinant of *Bacillus anthracis*. *Mol Microbiol* 81:1542–1559
34. Boehm M, Hoy B, Rohde M, Tegtmeyer N, Baek KT, Oyarzabal OA et al (2012) Rapid paracellular transmigration of *Campylobacter jejuni* across polarized epithelial cells without affecting TER: role of proteolytic-active HtrA cleaving E-cadherin but not fibronectin. *Gut Pathog* 4:3
35. Hoy B, Geppert T, Boehm M, Reisen F, Plattner P, Gadermaier G et al (2012) Distinct roles of secreted HtrA proteases from Gram-negative pathogens in cleaving the junctional protein and tumor suppressor E-cadherin. *J Biol Chem* 287:10115–10120
36. Hoy B, Lower M, Weydig C, Carra G, Tegtmeyer N, Geppert T et al (2010) *Helicobacter pylori* HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. *EMBO Rep* 11:798–804
37. Okuda J, Hayashi N, Tanabe S, Minagawa S, Gotoh N (2011) Degradation of interleukin 8 by the serine protease MucD of *Pseudomonas aeruginosa*. *J Infect Chemother* 17:782–792
38. Lower M, Weydig C, Metzler D, Reuter A, Starzinski-Powitz A, Wessler S et al (2008) Prediction of extracellular proteases of the human pathogen *Helicobacter pylori* reveals proteolytic activity of the Hp1018/19 protein HtrA. *PLoS One* 3:e3510
39. Lewis C, Skovierova H, Rowley G, Rezuchova B, Homerova D, Stevenson A et al (2009) *Salmonella enterica* Serovar Typhimurium HtrA: regulation of expression and role of the chaperone and protease activities during infection. *Microbiology* 155:873–881
40. Baud C, Hodak H, Willery E, Drobacq H, Lochet C, Jamin M et al (2009) Role of DegP for two-partner secretion in *Bordetella*. *Mol Microbiol* 74:315–329
41. Baek KT, Vegge CS, Brondsted L (2011) HtrA chaperone activity contributes to host cell binding in *Campylobacter jejuni*. *Gut Pathog* 3:13
42. Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A (2007) Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the *Bacillus anthracis* secretome. *Infect Immun* 75:2841–2852
43. Roop RM 2nd, Fletcher TW, Sriranganathan NM, Boyle SM, Schurig GG (1994) Identification of an immunoreactive *Brucella abortus* HtrA stress response protein homolog. *Infect Immun* 62:1000–1007
44. Roy K, Bartels S, Qadri F, Fleckenstein JM (2010) Enterotoxigenic *Escherichia coli* elicits immune responses to multiple surface proteins. *Infect Immun* 78:3027–3035
45. Chen HW, Zhang Z, Huber E, Chao CC, Wang H, Dasch GA et al (2009) Identification of cross-reactive epitopes on the conserved 47-kilodalton antigen of *Orientia tsutsugamushi* and human serine protease. *Infect Immun* 77:2311–2319
46. Haas G, Karaali G, Ebermayer K, Metzger WG, Lamer S, Zimny-Arndt U et al (2002) Immunoproteomics of *Helicobacter pylori* infection and relation to gastric disease. *Proteomics* 2:313–324
47. Sanchez-Campillo M, Bini L, Comanducci M, Raggiacchi R, Marzocchi B, Pallini V et al (1999) Identification of immunoreactive proteins of *Chlamydia trachomatis* by Western blot analysis of a two-dimensional electrophoresis map with patient sera. *Electrophoresis* 20:2269–2279
48. Weichhart T, Horky M, Sollner J, Gangl S, Henics T, Nagy E et al (2003) Functional selection of vaccine candidate peptides from *Staphylococcus aureus* whole-genome expression libraries in vitro. *Infect Immun* 71:4633–4641
49. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E et al (2011) Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of *Chlamydia trachomatis* vaccines. *Proc Natl Acad Sci USA* 108:9969–9974
50. Huston WM, Armitage CW, Lawrence A, Gloeckl S, Bell SJ, Debattista J et al (2010) HtrA, RseP, and Tsp proteins do not elicit a pathology-related serum IgG response during sexually transmitted infection with *Chlamydia trachomatis*. *J Reprod Immunol* 85:168–171
51. Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G (2010) A genome-wide profiling of the humoral immune response to *Chlamydia trachomatis* infection reveals vaccine candidate antigens expressed in humans. *J Immunol* 185:1670–1680
52. Jiao XD, Zhang M, Cheng S, Sun L (2010) Analysis of *Edwardsiella tarda* DegP, a serine protease and a protective immunogen. *Fish Shellfish Immunol* 28:672–677
53. Loosmore SM, Yang YP, Oomen R, Shortreed JM, Coleman DC, Klein MH (1998) The *Haemophilus influenzae* HtrA protein is a protective antigen. *Infect Immun* 66:899–906
54. Zhang WW, Sun K, Cheng S, Sun L (2008) Characterization of DegQ_{Vhr}, a serine protease and a protective immunogen from a pathogenic *Vibrio harveyi* strain. *Appl Environ Microbiol* 74:6254–6262
55. Li B, Zhou L, Guo J, Wang X, Ni B, Ke Y et al (2009) High-throughput identification of new protective antigens from a *Yersinia pestis* live vaccine by enzyme-linked immunospot assay. *Infect Immun* 77:4356–4361
56. Bae JE, Schurig GG, Toth TE (2002) Mice immune responses to *Brucella abortus* heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified *Brucella abortus* recombinant proteins, and a vaccinia virus recombinant as immunogens. *Vet Microbiol* 88:189–202
57. Rigoulay C, Entenza JM, Halpern D, Widmer E, Moreillon P, Poquet I et al (2005) Comparative analysis of the roles of HtrA-like surface proteases in two virulent *Staphylococcus aureus* strains. *Infect Immun* 73:563–572
58. Daum RS, Spellberg B (2012) Development of a vaccine against *Staphylococcus aureus*. *Semin Immunopathol* 34:335–348
59. Rokbi B, Lafont C (2010) Method for the production of overproducing *Staphylococcus aureus* strains. *US 20100880566 20100913 C12N1/20*
60. Lees JG, Smith BR, Wien F, Miles AJ, Wallace BA (2004) *CDtool*-an integrated software package for circular dichroism spectroscopic data processing, analysis, and archiving. *Anal Biochem* 332:285–289
61. Kern R, Malki A, Holmgren A, Richarme G (2003) Chaperone properties of *Escherichia coli* thioredoxin and thioredoxin reductase. *Biochem J* 371:965–972
62. Zhi W, Landry SJ, Gierasch LM, Srere PA (1992) Renaturation of citrate synthase: influence of denaturant and folding assistants. *Protein Sci* 1:522–529
63. Jakob U, Gaestel M, Engel K, Buchner J (1993) Small heat shock proteins are molecular chaperones. *J Biol Chem* 268:1517–1520
64. Wilken C, Kitzing K, Kurzbauer R, Ehrmann M, Clausen T (2004) Crystal structure of the DegS stress sensor: how a PDZ domain recognizes misfolded protein and activates a protease. *Cell* 117:483–494
65. Boyd D, Beckwith J (1990) The role of charged amino acids in the localization of secreted and membrane proteins. *Cell* 62:1031–1033
66. von Heijne G (1986) The distribution of positively charged residues in bacterial inner membrane proteins correlates with the trans-membrane topology. *EMBO J* 5:3021–3027
67. Kim DY, Kim KK (2005) Structure and function of HtrA family proteins, the key players in protein quality control. *J Biochem Mol Biol* 38:266–274
68. Cates GA, Yang YP, Klyushnichenko V, Oomen R, Loosmore SM (2000) Properties of recombinant HtrA: an otitis media vaccine candidate antigen from non-typeable *Haemophilus influenzae*. *Dev Biol (Basel)* 103:201–204
69. Zurawa-Janicka D, Jarzab M, Polit A, Skorko-Glonek J, Lesner A, Gitlin A et al (2013) Temperature-induced changes of HtrA2(Omi) protease activity and structure. *Cell Stress Chaperones* 18:35–51
70. Sobiecka-Szkatula A, Polit A, Scire A, Gieldon A, Tanfani F, Szkarlat Z et al (2009) Temperature-induced conformational changes within the regulatory loops L1–L2–LA of the HtrA heat-shock protease from *Escherichia coli*. *Biochim Biophys Acta* 1794:1573–1582
71. Spiess C, Beil A, Ehrmann M (1999) A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. *Cell* 97:339–347
72. Richarme G, Caldas TD (1997) Chaperone properties of the bacterial periplasmic substrate-binding proteins. *J Biol Chem* 272:15607–15612
73. Antelmann H, Darmon E, Noone D, Veening JW, Westers H, Bron S et al (2003) The extracellular proteome of *Bacillus subtilis* under secretion stress conditions. *Mol Microbiol* 49:143–156